Clinical Trials

Study Title:
A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer

For more information about the trial above please contact the study team:

Principal Investigator, Mariam Alexander, at alexanma@musc.edu.

Study Coordinator, Taryn Wheeler, at wheeleta@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina